Time Lag of Acromegaly Diagnosis and Associated Comorbidities in Sulaymaniyah City/Iraq

Aso Nasih Qadir; Taha Othman Mahwi; Zagros Ghaffor Rashid

doi:10.54133/ajms.v10i2.2875

Authors

Aso Nasih Qadir Candidate for Specialty in Endocrinology and Diabetes, Kurdistan Higher Council of Medical Specialties, Kurdistan Region, Iraq https://orcid.org/0009-0007-7677-1820
Taha Othman Mahwi Department of Clinical Science, College of Medicine, University of Sulaimani, Sulaimani, Kurdistan Region, Iraq https://orcid.org/0000-0001-9477-8814
Zagros Ghaffor Rashid Department of Clinical Science, College of Medicine, University of Sulaimani, Sulaimani, Kurdistan Region, Iraq https://orcid.org/0009-0000-0678-3112

DOI:

https://doi.org/10.54133/ajms.v10i2.2875

Keywords:

Acromegaly, Colonoscopy findings, Comorbidity burden , Diagnosis delay

Abstract

Background: Acromegaly is a rare endocrine disease. The insidious onset and symptom overlap with frequently found diseases, resulting in an often delayed diagnosis. Objective: To evaluate diagnostic delay in patients with acromegaly and its association with patient findings in Sulaymaniyah, Iraq. Methods: A retrospective cross-sectional study was conducted in 49 patients diagnosed with acromegaly. Patient data were collected through interviews and medical record review. The diagnostic delay was determined as the period between the onset of symptoms and the formal diagnosis. Results: The average diagnostic delay was 3.3 years, and the majority of patients were diagnosed with five years of symptom onset. Hypertension was observed in 32.7% of patients, and unemployment, lower education, cumulative comorbidity burden, and abnormal colonoscopy findings were significantly associated with longer delays. In patients <40 years old, the delay can be more extreme, wherein close to half had not undergone a colonoscopy. Normal finding (34.6%), polyps (15.4%), and malignancy (3.8%). However, in patients aged ≥40 years (46.9%), all underwent colonoscopy; 65.2% were normal, 26.1% had polyps, and 8.7% had malignancy. Overall, colorectal cancer was detected in three patients (6.1%), and there was a statistically significant correlation between age group and colonoscopic findings. Conclusions: Acromegaly diagnostic delay is substantial in the Kurdistan Region and is related to socioeconomic factors, asymptomatic onset, and comorbidity. Increased awareness, access to endocrinology, and broader colorectal screening are essential to improve outcomes.

Downloads

Download data is not yet available.

References

Wang K, Guo X, Yu S, Gao L, Wang Z, Zhu H, et al. Patient-identified problems and influences associated with diagnostic delay of acromegaly: A nationwide cross-sectional study. Front Endocrinol. 2021;12:704496. doi: 10.3389/fendo.2021.704496. DOI: https://doi.org/10.3389/fendo.2021.704496

Melmed S. Pituitary tumors. Endocrinol Metab Clin North Am. 2015;44(1):1-9. doi: 10.1016/j.ecl.2014.11.004. DOI: https://doi.org/10.1016/j.ecl.2014.11.004

Liu X, Wang R, Li M, Chen G. Pituitary adenoma or pituitary neuroendocrine tumor: A narrative review of controversy and perspective. Transl Cancer Res. 2021;10(4):1916-1920. doi: 10.21037/tcr-20-3446. DOI: https://doi.org/10.21037/tcr-20-3446

Bianchi A, Chiloiro S, Giampietro A, Gaudino S, Calandrelli R, Mazzarella C, et al. Multidisciplinary management of difficult/aggressive growth-hormone pituitary neuro-endocrine tumors. Front Endocrinol. 2023;14:1123267. doi: 10.3389/fendo.2023.1123267. DOI: https://doi.org/10.3389/fendo.2023.1123267

Zendran I, Gut G, Kaluzny M, Zawadzka K, Bolanowski M. Acromegaly caused by ectopic growth hormone releasing hormone secretion: A review. Front Endocrinol (Lausanne). 2022;13:867965. doi: 10.3389/fendo.2022.867965. DOI: https://doi.org/10.3389/fendo.2022.867965

Lenders NF, Earls PE, Inder WJ, Mccormack AI. The evolution in pituitary tumour classification: A clinical perspective. Endocr Oncol. 2023;3(1):e220079. doi: 10.1530/EO-22-0079. DOI: https://doi.org/10.1530/EO-22-0079

Ravindra VM, Raheja A, Corn H, Driscoll M, Welt C, Simmons DL, et al. Primary pituitary diffuse large b-cell lymphoma with somatotroph hyperplasia and acromegaly: Case report. J Neurosurg. 2017;126(5):1725-1730. doi: 10.3171/2016.5.JNS16828. DOI: https://doi.org/10.3171/2016.5.JNS16828

Dhaneshwar S, Shandily S, Tiwari V. Growth hormone excess: Implications and management. Endocr. Metab. Immune Disord. Drug Targets. 2023;23(6):748-763. doi: 10.2174/1871530322666221012155533. DOI: https://doi.org/10.2174/1871530322666221012155533

Elbaum M, Daroszewski J, Bolanowski M. Cardiovascular complications of acromegaly. Acta Endocrinol (Buchar.). 2018;14(3):365. doi: 10.4183/aeb.2018.365. DOI: https://doi.org/10.4183/aeb.2018.365

Rivera FB, Taliño MK, Ansay MF, Mangubat GF, Mahilum ML, Menghrajani RH, et al. Cardiovascular effects of excess growth hormone: How real is the threat? Rev Cardiovasc Med. 2023;24(4):95. doi: 10.31083/j.rcm2404095. DOI: https://doi.org/10.31083/j.rcm2404095

Dal J, Leisner MZ, Hermansen K, Farkas DK, Bengtsen M, Kistorp C, et al. Cancer incidence in patients with acromegaly: A cohort study and meta-analysis of the literature. J Clin Endocrinol Metab. 2018;103(6):2182-2188. doi: 10.1210/jc.2017-02457. DOI: https://doi.org/10.1210/jc.2017-02457

Hannon AM, Thompson CJ, Sherlock M. Diabetes in patients with acromegaly. Curr Diab Rep. 2017;17(2):8. doi: 10.1007/s11892-017-0838-7. DOI: https://doi.org/10.1007/s11892-017-0838-7

Giustina A, Barkan A, Beckers A, Biermasz N, Biller BMK, Boguszewski C, et al. A consensus on the diagnosis and treatment of acromegaly comorbidities: An update. J Clin Endocrinol Metab. 2020;105(4). doi: 10.1210/clinem/dgz096. DOI: https://doi.org/10.1210/clinem/dgz096

Algahtany M, Sharma S, Fahoum K, Jing R, Zhang S, Kovacs K, et al. The role of growth hormone in depression: A human model. Front Neurosci. 2021;15:661819. doi: 10.3389/fnins.2021.661819. DOI: https://doi.org/10.3389/fnins.2021.661819

Zahr R, Fleseriu M. Updates in diagnosis and treatment of acromegaly. Eur Endocrinol. 2018;14(2):57-61. doi: 10.17925/EE.2018.14.2.57. DOI: https://doi.org/10.17925/EE.2018.14.2.57

Chiloiro S, Giampietro A, Gagliardi I, Bondanelli M, Veleno M, Ambrosio MR, et al. Impact of the diagnostic delay of acromegaly on bone health: Data from a real life and long term follow-up experience. Pituitary. 2022;25(6):831-841. doi: 10.1007/s11102-022-01266-4. DOI: https://doi.org/10.1007/s11102-022-01266-4

Carroll PV, Joshi MN. Acromegaly. 2022 Sep 7. In: Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, et al, (editors). Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000. PMID: 25905322.

Fleseriu M, Langlois F, Lim DST, Varlamov EV, Melmed S. Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 2022;10(11):804-826. doi: 10.1016/S2213-8587(22)00244-3. DOI: https://doi.org/10.1016/S2213-8587(22)00244-3

Bai X, Duan L, Yang S, Wang T, Yao Y, Zhang M, et al. Biochemical remission, diagnostic delays, and comorbidities of acromegaly in china: A large single-centre retrospective study. Front Endocrinol (Lausanne). 2025;16:1526625. doi: 10.3389/fendo.2025.1526625. DOI: https://doi.org/10.3389/fendo.2025.1526625

Esposito D, Ragnarsson O, Johannsson G, Olsson DS. Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality. Eur J Endocrinol. 2020;182(6):523-531. doi: 10.1530/EJE-20-0019. DOI: https://doi.org/10.1530/EJE-20-0019

Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest. 2009;119(11):3189-3202. doi: 10.1172/JCI39375. DOI: https://doi.org/10.1172/JCI39375

Colao A, Grasso LF, Giustina A, Melmed S, Chanson P, Pereira AM, et al. Acromegaly. Nat Rev. Dis Primers. 2019;5(1):20. doi: 10.1038/s41572-019-0081-7. DOI: https://doi.org/10.1038/s41572-019-0071-6

Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary. 1999;2:29-41. doi: 10.1023/a:1009965803750. DOI: https://doi.org/10.1023/A:1009965803750

Chanson P, Salenave S. Acromegaly. Orphanet J Rare Dis. 2008;3(1):17. doi: 10.1186/1750-1172-3-17. DOI: https://doi.org/10.1186/1750-1172-3-17

Ben-Shlomo A, Melmed S. Acromegaly. Endocrinol Metab Clin North Am. 2008;37(1):101-122. doi: 10.1016/j.ecl.2007.10.002. DOI: https://doi.org/10.1016/j.ecl.2007.10.002

Adelman DT, Liebert KJ, Nachtigall LB, Lamerson M, Bakker B. Acromegaly: The disease, its impact on patients, and managing the burden of long-term treatment. Int J Gen Med. 2013;6:31-38. doi: 10.2147/IJGM.S38594. DOI: https://doi.org/10.2147/IJGM.S38594

Almalki MH, Elhadd T, Aldahmani KM, Ekhzaimy A, Alqanaei A, Frookh H, et al. Management of patients with acromegaly in clinical practice in the gulf countries: A delphi consensus survey. Front Endocrinol. 2025;16:1593959. doi: 10.3389/fendo.2025.1593959. DOI: https://doi.org/10.3389/fendo.2025.1593959

Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP. Mortality in acromegaly: A metaanalysis. J Clin Endocrinol Metab. 2008;93(1):61-67. doi: 10.1210/jc.2007-1191. DOI: https://doi.org/10.1210/jc.2007-1191

Katznelson L, Laws ER, Melmed S, Molitch ME, Murad MH, Utz A, et al. Acromegaly: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933-3951. doi: 10.1210/jc.2014-2700. DOI: https://doi.org/10.1210/jc.2014-2700

Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B, et al. Multidisciplinary management of acromegaly: A consensus. Rev Endocr Metab Disord. 2020;21(4):667-678. doi: 10.1007/s11154-020-09588-z. DOI: https://doi.org/10.1007/s11154-020-09588-z

Renehan AG, O'connell J, O'halloran D, Shanahan F, Potten CS, O'dwyer ST, et al. Acromegaly and colorectal cancer: A comprehensive review of epidemiology, biological mechanisms, and clinical implications. Horm Metab Res. 2003;35(11-12):712-725. doi: 10.1055/s-2004-814150. DOI: https://doi.org/10.1055/s-2004-814150